Anebulo Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -2,140 | -2,127 | -1,430 | -2,402 |
EBIT | -2,140 | 35 | -1,431 | -2,403 |
Net Income | -2,158 | -2,144 | -1,676 | -2,463 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -1,273 | -1,652 | -1,601 | -1,405 |
Cash | 10,354 | 11,627 | 13,279 | 14,998 |
Basic Shares | 41,084 | 41,084 | 27,415 | 27,415 |
Annual Financials
| Values in thousands | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -8,102 | -7,791 | -11,783 | -6,825 |
EBIT | -8,050 | -11,783 | -6,825 | |
Net Income | -8,484 | -8,202 | -11,732 | -6,825 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -6,349 | -8,090 | -9,683 | -5,437 |
Cash | 11,627 | 3,094 | 11,247 | 14,548 |
Basic Shares | 33,820 | 25,822 | 25,074 | 23,345 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.05 |
2025-06-30 | -$0.05 |
2025-03-31 | -$0.04 |
